Efficacy and Safety of Fexuprazan-Based Modified High-Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial. (PubMed, Helicobacter) - Jun 9, 2026 - "Fexuprazan-based m-HDDT with bismuth was non-inferior to PPI-based STT for H. pylori eradication and demonstrated comparable safety and excellent compliance. This clarithromycin-sparing regimen can be considered an alternative treatment option in regions with high macrolide resistance."
Clinical • Journal • Infectious Disease
|
|
Jae J Kim; Jeong Hwan Kim; Jeong Seop Moon; Ji Yong Ahn; Jung-Ho Park; Ki-Nam Shim; Sang Gyun Kim; Young Hoon Youn
|